Factor VIII in Acute Cerebral Ischemia Pilot Study: Biomarker in Patients With Large Vessel Occlusion?

Clin Appl Thromb Hemost. 2018 Nov;24(8):1249-1254. doi: 10.1177/1076029618781045. Epub 2018 Jun 12.

Abstract

We conducted a prospective serial laboratory cohort study to assess the correlation of factor VIII (FVIII) levels in response to thrombolysis in patients with large vessel occlusion (LVO) and acute ischemic stroke (AIS). Patients with AIS with anterior circulation LVO were eligible for enrollment if treated within 4.5 hours from last seen normal with intravenous tissue plasminogen activator (tPA). Patients (n = 29) had a mean age of 71 years and median National Institute of Health Stroke Scale of 14. Baseline pre-tPA FVIII was not significantly correlated with clot burden score (-0.147, P = .447) or vessel recanalization (-0.133, P = .499). Median FVIII decreased significantly from baseline to 6 hours post-tPA (282% to 161%, P = .002), but delta in FVIII level did not correlate with vessel recanalization (0.013, P = .948). There was no difference between median FVIII level at baseline and 90 days post-AIS. FVIII level decreased significantly after tPA, but baseline FVIII level and early change in FVIII level were not significant predictors of clot burden, vessel recanalization after thrombolysis, or symptomatic hemorrhage.

Keywords: biomarkers; factor VIII; pilot study; stroke.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Brain Ischemia* / blood
  • Brain Ischemia* / drug therapy
  • Factor VIII / metabolism*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Stroke* / blood
  • Stroke* / drug therapy
  • Thrombolytic Therapy*
  • Thrombosis* / blood
  • Thrombosis* / drug therapy
  • Time Factors
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Biomarkers
  • F8 protein, human
  • Factor VIII
  • Tissue Plasminogen Activator